Table 3.
Medication use
| Variable | Netherlands (%) | Germany (%) | France (%) | p-value | Total study population (%) |
|---|---|---|---|---|---|
| Pre-procedure (in ambulance) | |||||
| Acetylsalicylic acid | 375/407 (92) | 134/165 (81) | 118/131 (90) | 0.001 | 838/950 (88) |
| P2Y12 inhibitor | 331/407 (81) | 89/165 (54) | 108/131 (82) | <0.00001 | 709/950 (75) |
| Heparin | 300/407 (74) | 76/165 (46) | 66/131 (50) | <0.00001 | 574/950 (60) |
| Pre- and/or peri-procedure | |||||
| Acetylsalicylic acid | 393/407 (97) | 154/165 (93) | 125/131 (95) | 0.233 | 897/950 (94) |
| P2Y12 inhibitor | 380/407 (93) | 131/165 (79) | 124/131 (95) | <0.00001 | 863/950 (91) |
| Heparin | 381/407 (94) | 154/165 (93) | 89/131 (68) | <0.00001 | 825/950 (87) |
| Bivalirudin | 46/407 (11) | 1/165 (1) | 3/131 (2) | <0.00001 | 109/950 (12) |
| Glycoprotein IIb/IIIa inhibitor | 147/407 (36) | 60/165 (36) | 59/131 (45) | 0.169 | 357/950 (38) |
| Discharge | |||||
| Acetylsalicylic acid | 408/418 (98) | 162/165 (98) | 128/130 (99) | 0.804 | 941/960 (98) |
| P2Y12 inhibitor | 418/418 (100) | 162/165 (98) | 130/130 (100) | 0.007 | 954/960 (99) |
| On DAPT | 408/418 (98) | 162/165 (98) | 128/130 (99) | 0.804 | 939/960 (98) |
DAPT dual antiplatelet therapy